Novartis AG (LTS:0QM7) Accounts Payable: CHF3,403.42 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Novartis AG Accounts Payable?

Novartis AG LTS:0QM7 80 Accounts Payable is CHF3,403.42 Mil as of Jun. 2026. GuruFocus rates LTS:0QM7 with a GF Score™ of 80/100. The stock has 7 warning signs investors should review.

Novartis AG's Accounts Payable for the quarter that ended in Jun. 2026 was CHF3,403.42 Mil.

Novartis AG's quarterly Accounts Payable declined from Dec. 2025 (CHF3,550.99 Mil) to Mar. 2026 (CHF3,402.71 Mil) but then increased from Mar. 2026 (CHF3,402.71 Mil) to Jun. 2026 (CHF3,403.42 Mil).

Novartis AG's annual Accounts Payable declined from Dec. 2023 (CHF4,260.01 Mil) to Dec. 2024 (CHF4,076.40 Mil) and declined from Dec. 2024 (CHF4,076.40 Mil) to Dec. 2025 (CHF3,550.99 Mil).

Novartis AG Accounts Payable Historical Data

* Premium members only.

The historical data trend for Novartis AG's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Accounts Payable Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,114.31 4,794.01 4,260.01 4,076.40 3,550.99

Novartis AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,664.28 3,626.24 3,550.99 3,402.71 3,403.42

Novartis AG Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF3,403.42 Mil mean?
Novartis AG (LTS:0QM7) has a Accounts Payable of CHF3,403.42 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Novartis AG and its competitors.
Is Novartis AG's Accounts Payable too high?
Novartis AG's current Accounts Payable is CHF3,403.42 Mil. Overall, Novartis AG has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Accounts Payable compare to LLY and JNJ?
Novartis AG's Accounts Payable of CHF3,403.42 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Novartis AG and its competitors. Novartis AG's current Accounts Payable is CHF3,403.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (LTS:0QM7) has a current Accounts Payable of CHF3,403.42 Mil. The current Accounts Payable is CHF3,403.42 Mil. Novartis AG's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Novartis AG (LTS:0QM7), the current Accounts Payable is CHF3,403.42 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.